Aldo Mateo Torracchi Carrasco

Aldo Mateo Torracchi Carrasco

Auto-generated profile, based on publicly available information

Aldo Mateo Torracchi Carrasco

Universidad del Azuay, Facultad de Medicina, Cuenca, Ecuador

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2017 in Revista Médica Hospital del José Carrasco Arteaga
Verified
Journal Article
Open access
PDF file
PTPablo Gerardo Peña Tapia
Pablo Gerardo Peña Tapia
JAJHONATAN HERIBERTO VAZQUEZ ALBORNOZ
JHONATAN HERIBERTO VAZQUEZ ALBORNOZ
BOBlasco Danilo Moscoso Orellana
Blasco Danilo Moscoso Orellana
RSRene Sebastián Martínez Sánchez
Rene Sebastián Martínez Sánchez
ACAldo Mateo Torracchi Carrasco
Aldo Mateo Torracchi Carrasco
JRJohann Franz Radax
Johann Franz Radax
Caso Clínico: Uso de Biomodelos Tridimensionales para la planificación preoperatoria de Tumores Craneales fronto-orbitarios

30 November 2017 in Revista Médica Hospital del José Carrasco Arteaga
Verified
Journal Article
Open access
PDF file
ACAldo Mateo Torracchi Carrasco
Aldo Mateo Torracchi Carrasco
JRJohann Franz Radax
Johann Franz Radax
MAMarisa Arcos
Marisa Arcos
SZSandra Patricia Ochoa Zamora
Sandra Patricia Ochoa Zamora
MQMarco Vinicio Palacios Quezada
Marco Vinicio Palacios Quezada
CSCarla Salgado
Carla Salgado

31 July 2020 in Revista Médica Hospital del José Carrasco Arteaga
Verified
Journal Article
Closed access
PDF file
CSCarlos Joaquín Córdova Serrano
Carlos Joaquín Córdova Serrano
MOMaría Belén Saavedra Ortega
María Belén Saavedra Ortega
DPDiego Patricio Serrano Piedra
Diego Patricio Serrano Piedra
ACAldo Mateo Torracchi Carrasco
Aldo Mateo Torracchi Carrasco
BACKGROUND: Supraventricular tachycardia is commonly diagnosed in clinical practice, despite having a good prognosis, it can significantly affect the patient’s life quality. Pharmacological treatment does not result in the total absence of the arrhythmia, which is why ablation therapy has become the treatment of choice, due to its high success rate, and for offering a definitive solution. The aim of this study was to determine the frequency of each supraventricular tachycardia type, according to age and sex, the rate of success of percutaneous ablation and its related factors, and the frequency of complications due to the procedure. METHODS: A cross-sectional, descriptive, correlational study was conducted, including 156 patients diagnosed with supraventricular tachycardia and ablated, from five hospitals where the procedure was performed, based on their clinical records. RESULTS: From the 156 patients in this study, 51.9% were women and 48.1% men, the age ranged between 10 and 80 years. The most commonly reported arrhythmias were nodal reentrant tachycardia, atrioventricular reentrant tachycardia and atrial flutter, being the atrioventricular reentrant tachycardia the most frequent of all. The global success rate was 93.5%, no complications were reported, and none of the studied factors had significant statistical association with the success rate. CONCLUSION: Ablation treatment had a high success rate, with cero complications in this study, demonstrating the efficacy and safety of the procedure.

1 December 2025 in Respirar
Verified
Journal Article
Open access
PDF file
ATAldo Torracchi
Aldo Torracchi
Obstructive sleep apnea (OSA) is the most prevalent chronic respiratory disease worldwide. According to some studies, it may affect up to 25% of the global population, with its presentation varying based on age group, sex, nutritional status, ethnicity and other factors. Despite its high prevalence and the significant impact it has on overall health, OSA remains largely underdiagnosed. By general consensus, polysomnography (PSG) is considered the gold standard for the diagnosis and staging of OSA. However, this method is costly, complex and not widely accessible. In this context, new technologies integrating multimodal sensors capable of ambulatory monitoring circadian rhythm, physical activity and sleep structure, among other parameters, are emerging. Their use is increasingly widespread, promising to become innovative tools for large-scale OSA screening and other sleep disorders. Devices such as smartwatches, rings and smartphones have been extensively studied and have demonstrated acceptable capability when compared to PSG, with many achieving a sensitivity (Se) close to 90% and specificity (Sp) of 80%. Despite the advancements implied by the development of these new health technologies, it is important to consider that the capability of these devices varies depending on the specific equipment and the populations studied. Much of this widely available emerging technology lacks external validation or requires further studies; therefore, it is crucial that its use is regulated by governmental institutions, healthcare services, or other independent organizations.